Less is more ? De-intensification of therapy for early-stage HER2-positive breast cancer
Mené sur 151 patientes atteintes d'un cancer invasif du sein HER2+ de stade I à IIIA (âge : 18 ans et plus), cet essai multicentrique de phase II évalue l'association entre le sous-type moléculaire "HER2 enrichi" et la réponse pathologique complète à un traitement par inhibiteur du récepteur HER2
De-intensification of breast cancer treatment is a laudable goal. Fewer aggressive breast and axillary surgeries are now needed to achieve excellent outcomes, and genomic assays can help to identify patients in whom adjuvant chemotherapy can be omitted.1 Although chemotherapy remains the backbone on which HER2-targeted therapy is used in patients with early-stage HER2-positive breast cancer, treatment de-intensification in these patients is receiving increasing attention. Non-anthracycline-based chemotherapy is now part of the standard of care, and shorter courses of chemotherapy can be appropriate in the management of early-stage, node-negative, HER2-positive breast cancer.
The Lancet Oncology , commentaire, 2016